Pasithea has announced the commencement of a Phase I/Ib open-label trial of PAS-004 for treating adults with ...

Nuvig Therapeutics has dosed the first subject in its Phase II INVGOR trial of NVG-2089 for individuals with CIDP.

ADC Therapeutics has pulled the drug candidate from development, leaving it with one remaining clinical asset.

This follows what appeared to be a generally positive data readout for belrestotug at ESMO 2024 just a few months ago.

BridgeBio Pharma has dosed the first subject in the ACT-EARLY study of acoramidis, a drug intended to prevent transthyretin ...

Roche has reported overall survival outcomes from a Phase III trial of Perjeta with Herceptin and chemotherapy in early-stage ...

People with bipolar disorder (BD) who have experienced childhood trauma (CT) will frequently document having more depressive ...

Connect Biopharma has begun a Phase II trial to assess rademikibart for treating acute exacerbations of asthma and type II ...

The EMA has approved Moleculin Biotech’s CTA for a Phase IIb/III trial of Annamycin plus cytarabine (Ara-C) for AML.

The human immunodeficiency virus (HIV) market across the seven major markets (7MM), comprising the US, France, Germany, Italy ...

GlobalData analysis predicts the global GLP-1RA market will reach $168bn by 2033, with Novo Nordisk and Eli Lilly to dominate ...

The Danish multinational said that Sogroya improved the yearly growth rate in pre-pubertal children born small for ...